600812 Stock Overview
Engages in the research and development, production, and sales of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
North China Pharmaceutical Company.Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.34 |
| 52 Week High | CN¥6.22 |
| 52 Week Low | CN¥3.83 |
| Beta | 1.03 |
| 1 Month Change | -4.47% |
| 3 Month Change | 3.89% |
| 1 Year Change | -6.32% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600812 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.4% | -1.9% | -0.6% |
| 1Y | -6.3% | -5.7% | 8.3% |
Return vs Industry: 600812 matched the CN Pharmaceuticals industry which returned -5.7% over the past year.
Return vs Market: 600812 underperformed the CN Market which returned 8.3% over the past year.
Price Volatility
| 600812 volatility | |
|---|---|
| 600812 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.9% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600812 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600812's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 10,159 | Xin Yan Liu | www.ncpc.com |
North China Pharmaceutical Company Ltd engages in the research and development, production, and sales of pharmaceutical products in China. The company primarily offers anti-infective drugs; biotechnology drugs; cardiovascular cerebrovascular; immunomodulators; and vitamins and health products.
North China Pharmaceutical Company.Ltd Fundamentals Summary
| 600812 fundamental statistics | |
|---|---|
| Market cap | CN¥9.16b |
| Earnings (TTM) | CN¥79.38m |
| Revenue (TTM) | CN¥9.71b |
115.4x
P/E Ratio0.9x
P/S RatioIs 600812 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600812 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.71b |
| Cost of Revenue | CN¥6.74b |
| Gross Profit | CN¥2.97b |
| Other Expenses | CN¥2.89b |
| Earnings | CN¥79.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 0.046 |
| Gross Margin | 30.61% |
| Net Profit Margin | 0.82% |
| Debt/Equity Ratio | 172.4% |
How did 600812 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 00:55 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
North China Pharmaceutical Company.Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hongbao Zhang | China Merchants Securities Co. Ltd. |
| Jie Yao | Citic Securities Co., Ltd. |
| null Research Department | Guotai Junan International Holdings Limited |